This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Javaid, M K. Articles by Holt, R. I. Search for Related Content PubMed PubMed Citation Articles by Javaid, M K. Articles by Holt, R. I. Pubmed/NCBI databases Medline Plus Health Information Fractures Mental Health Osteoporosis Social Bookmarking                   What's this?

Understanding osteoporosis

MRC Epidemiology Resource Centre, Development Origins of Health and Disease Division, School of Medicine, University of Southampton, Southampton, UK

Richard IG Holt

Endocrinology and Metabolism Subdivision, Development Origins of Health and Disease Division, School of Medicine, University of Southampton, Southampton, UK, righ{at}soton.ac.uk

Osteoporosis is a common skeletal condition that results in significant morbidity, mortality and health care costs. There is an increased awareness of bone health in people with severe mental illness (SMI). These people appear to be at a higher risk of low bone density and fracture, and also have a poorer outcome following hip fracture. The reason for the increased risk of osteoporosis is multifactorial and includes general as well as disease-specific factors, such as antipsychotic medication and hyperprolactinaemia. Clinical history and examination followed by dual energy x-ray absorptiometry are required to assess the risk of osteoporosis. Therapies should begin with lifestyle measures, such as physical activity and dietary supplementation, with the use of bone-specific agents reserved for those at high absolute risk.

Journal of Psychopharmacology, Vol. 22, No. 2 suppl, 38-45 (2008)
DOI: 10.1177/0269881107087955


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V. O'Keane Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia J Psychopharmacol, March 1, 2008; 22(2_suppl): 70 - 75. [Abstract] [PDF]

				J. Walters and I. Jones Clinical questions and uncertainty -- prolactin measurement in patients with schizophrenia and bipolar disorder J Psychopharmacol, March 1, 2008; 22(2_suppl): 82 - 89. [Abstract] [PDF]